This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Baxter International Inc. (NYSE:BAX) today announced it has appointed two new members to its Board of Directors, Uma Chowdhry, PhD, and Thomas F. Chen. The appointments are effective November 2012.
Chowdhry most recently served as Senior Vice President and Chief Science and Technology Officer at E.I. du Pont de Nemours before retiring in 2010. She started her career at DuPont in 1977 as a research scientist and held positions of increasing responsibility. Chowdhry holds a bachelor’s of science degree in physics and math from Mumbai University, a master’s degree in engineering science from California Institute of Technology and a PhD in materials science from Massachusetts Institute of Technology.
Chen most recently served as Senior Vice President, International Nutrition, at Abbott before retiring in 2010. During his Abbott career, he served in a number of roles of increasing responsibility, primarily in Pacific/Asia/Africa where he oversaw expansion into a number of emerging markets. Chen started his career with American Cyanamid in 1979 and earned a bachelor’s degree in international business from National Cheng Chi University in Taipei, and a master’s in business administration from Indiana University.
''The appointments of Uma and Thomas deepen the strength of the Baxter Board of Directors and align with our history of scientific and product innovation, and our international presence as a company,'' said Robert L. Parkinson, Jr., Baxter’s Chairman and Chief Executive Officer.
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.